title: Survival benefit of the late percutaneous coronary intervention in the patients after acute myocardial infarction who are or who are not treated with thrombolysis.
abstract: The impact of late percutaneous coronary intervention (PCI) in the patients after acute myocardial infarction (AMI) on long term mortality remains to be established. At currently, thrombolysis is accepted as standard therapy when PCI is not immediately available. However, PCI is often performed in stable patients with AMI who are/are not received thrombolysis . We performed the trial that enrolled myocardial infarction patients treated with thrombolysis, late PCI and medically to assess the potential benefits of delayed PCI. We follow up 164 consecutive patients after AMI one year. The patients are divided in two groups; first group-66 patients who received reperfusion (37 patients received only thrombolysis, 10 patients received thrombolysis and PCI 7-9 days after thrombolysis and 19 patients underwent only PCI after 7-9 days) and second group-98 patients medically treated. One year mortality was 3% in the reperfusion group (2/66) and 14,3% in the medical group (14/98) (p=0,016). There were not significant differences between groups about other end points-reinfarctus, coronary artery bypass surgery and PCI performed later after discharge. The major predictors of one year mortality were ages (p<0,001) and ejection fraction (p=0,003). Also, therapy with beta-blockers (p=0,002), statins (p=0,001) and ACE-inhibitors (p=0,024) was associated with better survival. Delayed PCI performed 7-9 days after AMI in the patients who underwent thrombolysis or those did not improves outcome at long-term follow-up.
authors.affiliation: Clinical Center of Montenegro, Center of Cardiology, Podgorica, Ljubljanska bb, 81000 Podgorica, Montenegro.
authors.forename: Bozidarka
authors.initials: B
authors.lastname: Knezević
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Bulatović
authors.forename: Natasa
authors.initials: N
authors.lastname: Belada
authors.forename: Vesna
authors.initials: V
authors.lastname: Ivanović
authors.forename: Sinisa
authors.initials: S
authors.lastname: Dragnić
authors.forename: Miroslav
authors.initials: M
authors.lastname: Rabrenović
authors.forename: Goran
authors.initials: G
authors.lastname: Nikolić
authors.forename: Ljilja
authors.initials: L
authors.lastname: Musić
authors.forename: Aneta
authors.initials: A
authors.lastname: Bosković
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003402:Creatine Kinase / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism; D011379:Prognosis; D015912:Thrombolytic Therapy; D019210:Troponin I / Q000378:metabolism
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019210:Troponin I; D003402:Creatine Kinase